Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | FDPS | P14324 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23187794 | 1.00 | GPR84 (0.37) | GPR84LMNASMN1; SMN2ALDH1A1CYP2C19 | |
| SCHEMBL22060529 | 0.83 | EP300 (0.34) | SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL24529739 | 0.83 | EP300 (0.34) | SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL20334523 | 0.74 | CYP2C19 (0.51) | SMN1; SMN2ALDH1A1CYP2C19 | |
| SCHEMBL23353346 | 0.74 | CYP2C19 (0.51) | SMN1; SMN2ALDH1A1CYP2C19 | |
| SCHEMBL20334744 | 0.74 | CYP2C19 (0.51) | SMN1; SMN2ALDH1A1CYP2C19 | |
| SCHEMBL22106705 | 0.74 | CYP2C19 (0.51) | SMN1; SMN2ALDH1A1CYP2C19 | |
| SCHEMBL21392349 | 0.73 | EP300 (0.35) | SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL20334783 | 0.70 | FGFR1 (0.39) | — | |
| SCHEMBL21886597 | 0.67 | MEN1 (0.37) | LMNASMN1; SMN2ALDH1A1CYP2C19FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10745435-B2 | Nucleic acid prodrugs | CERECOR, INC. (US) | 2020-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10745435-B2 | Nucleic acid prodrugs | POLRMT, FPGS, POLN | GPR84 2310/4885LMNA 535/4885SMN1; SMN2 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.